Daniel Carcillo On Psychedelics For TBI, Wesana Partnering With MAPS & Mike Tyson Collaboration

During our time at Wonderland Miami, $PSYC CEO, David Flores, had the pleasure of sitting down with Wesana Health CEO, Daniel Carcillo, to talk about the significance of the conference and what it means to the arrival of the psychedelics industry. They also spent some time discussing Wesana’s collaboration with MAPS and the value that Mike Tyson is helping to create as a strategic partner to Wesana.
In this episode, you’ll be able to learn more about:
– Wesana’s collaboration on MAPS
– Maps accelerating TBI much faster
– Mike Tyson partnership significance
– Removing psychedelics’ stigma and describing them as medicines,
– The most important psychedelic highlights of 2021

#DanielCarcillo #Psychedelics #Wesana

source

Psychedelic Spotlight

Numinus’ BIG Patent, Mydecine Tackles A $13.6 BILLION Market & Some BUY Ratings! ( NUMI / MYCO)

June 29, 2021June 2, 2024 Listen, Videos

BIG news for Mydecine (MYCO : NEO) (MYCOF: OTC) and Numinus Wellness (NUMI: NEO)
(LKYSF : OTC). But The BIGGER NEWS is that we are finally launching our website: https://thepsychedelicinvestor.com/, where we will be sharing the latest industry news for all of your favorite companies.
We hope we can facilitate our community’s path to information about the psychedelic sector. We would like to invite you to share your opinions and suggestions down in the comment section.

Last but not least, if you wish to collaborate and become a contributor for The Psychedelic Investor, you’re welcome to send us an email at thepsychedelicinvestor@gmail.com or fill in a form on our website! We welcome your opinion and you can have a shot at seeing your name in the opinion section of our website!

Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!

Links:

Numinus Wellness (TSXV: NUMI, OTC: LKYSF), Filed a Patent Application for their Proprietary Rapid Production Process of Psilocybe Mushrooms and Other Psychoactive Fungi Species:
https://thepsychedelicinvestor.com/2021/06/24/numinus-files-u-s-provisional-patent-application-for-a-proprietary-rapid-production-process-for-psilocybe-and-other-psychoactive-fungi-species/

Mydecine (NEO: MYCO, OTC: MYCOF), Will Attempt To Treat Substance Use Disorder and Nicotine Addiction With Their MYCO-004 Molecule:
https://thepsychedelicinvestor.com/2021/06/24/mydecine-selects-substance-use-disorder-and-smoking-cessation-for-novel-psychedelic-molecule-myco-004/

Mydecine’s 4 Proprietary Compounds Advancing To Clinical Trials: Myco 001, 002, 003, 004:
https://thepsychedelicinvestor.com/2021/04/07/mydecine-announces-four-lead-novel-drug-candidates-and-prepares-for-pre-ind-meetings-with-the-fda-and-health-canada-to-prepare-for-human-clinical/

Johns Hopkins psilocybin study results:
https://www.hopkinsmedicine.org/news/stories/mushrooms_quit_smoking.html

Roth Capital Initiates Coverage On Mydecine Innovations with Buy Rating, Announces Price Target of 3$:
https://www.benzinga.com/news/21/06/21664391/roth-capital-initiates-coverage-on-mydecine-innovations-with-buy-rating-announces-price-target-of-c

Enjoy the episode!

Timestamps:
0:00 – Intro
1:37- Numinus’ patent application to speed up their psilobe mushrooms’ production process
4:53 – Mydecine announces it will use their MYCO – 004 molecule to treat substance use disorder and addiction
9:15 – Roth Capital says that Mydecine is a BUY with a price target of $3

Want to collaborate? Send us an email at:
thepsychedelicinvestor@gmail.com

Music from:
www.bensound.com

Video editing: @themyaholy

Check out our Benziga discounts
https://benzinga.grsm.io/jameshallifax1834
https://benzinga.grsm.io/thepsychedelicinvestor

DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.

All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.

#Numinus #Mydecine #NUMIStock

MindMed’s LSD Neutralizer is GENIUS: MindMed Stock’s Massive Opportunity (MMED/MMEDF) 🚀

January 3, 2021June 2, 2024 Listen, Videos

In this video, I discuss how MindMed’s LSD Neutralizer is GENIUS: MindMed Stock’s Massive Opportunity (MMED/MMEDF. 🔥

MindMed has had a impressive run up in 2020. The MMED stock is up nearly 1,130% and what we all wonder is : Could MindMed Stock keep on rising? With a larger psychedelic pipeline than Compass Pathways (CMPS), MindMed has made huge advancements in 2020, one of which is its LSD Neutralizer Technology To Shorten and Stop LSD Trips, which is groundbreaking news for all players in the psychedelic medicines industry.

MindMed has a handful of exciting programs in the works, some of which have important milestones coming up this year. Project Lucy is one of these programs, using therapeutic doses of LSD to treat anxiety disorders. If this gets the go-ahead from regulators, it will proceed with a clinical trial investigating LSD for anxiety disorders. If that happens, the mindmed stock could get a big boost. Another boost could be MindMed’s potential uplisiting on to the Nasdaq.

Currently, the MindMed Stock trades on the Canadian exchange NEO under the symbol MMED. MindMed is also traded in the United States under the symbol MMEDF and in Germany under the symbol MMQ.

Remember to Like, Subscribe, and SMAH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!

#MindMedStock #MindMed #MMED #MMEDF

Hawaii Moves to Legalize Psilocybin Treatment

March 3, 2021June 2, 2024 Listen, Psychedelic Spotlight Videos

Hawaii may soon be more than just Paradise. It may also be a psychedelic therapy hub. A new state measure aims to legalize psilocybin, the hallucinogenic compound in certain mushrooms.

Fungus Among Us: 5 Fascinating Facts About Mushrooms🍄

May 19, 2022June 2, 2024 Listen, Psychedelic Spotlight Videos

Join our Newsletter (scroll to the bottom of the page…

Interview with James Lanthier, CEO of Mindset Pharma

October 6, 2021June 2, 2024 Interviews, Listen, Podcasts

In our conversation, James goes into detail about Mindset’s new lead drug candidate MSP-1014, when the company expects to take the drug to clinical trials, and why next generation drugs are an important commercial opportunity for anyone looking to invest in the psychedelic sector.

BIG UPDATE On The LARGEST Psychedelic Therapy Clinical Trial: CMPS’ Psilocybin-Depression Study

July 14, 2021June 2, 2024 Listen, Videos

HUGE UPDATE: Compass Pathways, (NASDAQ: CMPS), completes the LARGEST Phase 2b psilocybin clinical study to treat treatment resistant depression (TRD).

This is the most important psychedelic therapy study that we know of because it is both the largest clinical trial testing psilocybin to date and it is also the most advanced in the clinical trial process.

In this episode we will discuss:
– The details of this trial and why it is so important;
– The big update that we have for you;
– When we can expect results;
– Where the field goes from here in the near future.

Timestamps:

0:00 – Intro
1:31 – What is Compass Pathways’ Phase2b trial and why is it important?
6:57 – The major Update on CMPS’ Clinical Trial
8:07 – Anticipated results date & what these results will mean for the psychedelic industry